DOI: 10.5683/sp3/lva2ek
title: Search Strategies: Sex differences in trial representation and the cardiovascular effectiveness and safety of newer glucose-lowering agents in patients with and without type 2 diabetes

description: The notes field contains the full MEDLINE (Ovid) search strategy for Sex differences in trial representation and the cardiovascular effectiveness and safety of newer glucose-lowering agents in patients with and without type 2 diabetes: A systematic meta-analysis of cardiovascular outcome trials. The file in this dataset contains the full MEDLINE (Ovid), EMBASE (Ovid), CENTRAL (Wiley) search strategies run on March 10, 2025
description: Ovid MEDLINE(R) Epub Ahead of Print and In-Process, In-Data-Review & Other Non-Indexed Citations and Daily 
 
1 Sodium-Glucose Transporter 2 Inhibitors/ 7751
2 (gliflozin* or (sglt-2 adj1 inhibitor*) or (sodium glucose transporter adj1 inhibitor*)).tw,kf. 2231
3 Canagliflozin/ 1171
4 (Canagliflozin* or Invokamet* or Invokana* or Prominad* or Sulisent*).tw,kf. 1951
5 (Dapagliflozin* or Farxiga* or Forxiga* or Qtern* or Xigduo XR*).tw,kf. 3432
6 (Empagliflozin* or Glyxambi* or Jardiance* or Synjardy*).tw,kf. 3490
7 (Ertugliflozin* or Segluromet* or Steglatro* or Steglujan*).tw,kf. 320
8 (inpefa* or Sotagliflozin* or Zynquista*).tw,kf. 244
9 (Bexagliflozin* or Brenzavvy*).tw,kf. 32
10 Glucagon-Like Peptide-1 Receptor Agonists/ 620
11 Glucagon-Like Peptide-1 Receptor/ 5982
12 (glp 1 analog* or glp1 analog or (glucagon like peptide* adj1 analog*) or (glp adj1 receptor adj1 agonist*) or (glucagon like peptide* adj1 agonist*) or (glucagon like peptide adj1 receptor adj1 agonist*) or incretin mimetic*).tw,kf. 2459
13 (Adlyxin* or Lixisenatide*).tw,kf. 628
14 Liraglutide/ 2876
15 (Liraglutide* or Saxenda* or Victoza*).tw,kf. 4597
16 Exenatide/ 3046
17 (bydureon* or byetta* or exenatide* or exendin*).tw,kf. 4976
18 (Ozempic* or Rybelsus* or Semaglutide* or Wegovy*).tw,kf. 2641
19 (Dulaglutide* or Trulicity*).tw,kf. 929
20 (Albiglutide* or Eperzan* or Tanzeum*).tw,kf. 260
21 (Efpeglenatide* or Lextemy*).tw,kf. 41
22 or/1-21 [SGLT-2 & GLP-1 Concept] 27412
23 exp Cardiovascular System/ 1396701
24 exp Cardiovascular Diseases/ 2852243
25 exp Heart Diseases/ 1326072
26 (heart adj1 (attack* or disease* or disorder* or event* or failure* or outcome* or risk*)).tw,kf. 450591
27 (coronary adj1 (attack* or disease* or disorder* or event* or failure* or outcome* or risk*)).tw,kf. 39578
28 (cardiac adj1 (arrest* or attack* or disease* or disorder* or event* or failure* or outcome* or risk*)).tw,kf. 122921
29 (cardiovasc* adj1 (attack* or death or disease* or disorder* or event* or failure* or outcome* or risk*)).tw,kf. 381561
30 (myocardi* adj1 (attack* or disease* or disorder* or event* or failure* or infarction* or outcome* or risk*)).tw,kf. 235511
31 (unstable adj1 angina).tw,kf. 14794
32 (circulator* adj1 (attack* or disease* or disorder* or event* or failure* or infarction* or outcome* or risk*)).tw,kf. 7364
33 exp Renal Insufficiency/ 216351
34 ((kidney or renal) adj3 (disease* or disorder* or injur* or failure* or insufficienc*)).tw,kf. 382368
35 exp Stroke/ 189278
36 (Apoplexy or Cerebrovascular accident* or brain attack* or stroke*).tw,kf. 366897
37 exp Kidney Diseases/ 600935
38 ((diabetic* or kidney or renal) adj3 (disease* or disorder* or injur* or failure* or glomeruloscleros* or insufficienc* or nephropath* or nephropath*)).tw,kf. 409828
39 ae.fs. 2105810
40 or/23-39 [Cardiovascular System] 6048348
41 (cardiovascular adj1 outcome adj1 trial*).mp. 879
42 (cardiovascular adj1 outcome adj1 stud*).mp. 93
43 (cardiovascular adj1 outcome adj1 result*).mp. 57
44 CVOT*.mp. 372
45 Outcome Reduction With Initial Glargine Intervention*.mp. 29
46 (AMPLITUDE-O or CARMELINA or DAPA or DAPA-MI or DARE-19 or DECLARE-TIMI or ELIXA or EMPA-KIDNEY or EMPA-REG or EMPEROR-Preserved or EMPEROR-REDUCED or EXSCEL or FIDELIO or FIGARO or FREEDOM-CVO or NCT01455896 or PIONEER-6 or SOLOIST-WHF or STEP-HFpEF or SUSTAIN-6 or TECOS or VERTIS-CV).mp. 2388
47 ((CANVAS* adj5 (trial* or stud* or investigat* or program* or outcome*)) or ((CLEAR adj5 (trial* or stud* or investigat* or program* or outcome*)) and bempedoic) or (FREEDOM adj1 cardiovasc* adj1 outcome*) or (HARMONY adj5 (trial* or stud* or investigat* or program* or outcome*)) or (REWIND adj5 (trial* or stud* or investigat* or program* or outcome*)) or ((SELECT adj5 (trial* or stud* or investigat* or program* or outcome*)) and semaglutide) or ((STEP adj5 (trial* or stud* or investigat* or program* or outcome*)) and semaglutide*) or (SURMOUNT adj5 (trial* or stud* or investigat* or program* or outcome*)) or (SURPASS? adj5 (trial* or stud* or investigat* or program* or outcome*))).mp. 1375
48 ((CAROLINA* and (linagliptin or glimepiride)) or (CREDENCE and Canagliflozin) or (DELIVER and Dapagliflozin) or (FIDELITY and Finerenone*) or (FREEDOM adj1 cardiovasc* adj1 outcome*) or (LEADER and Liraglutide) or (ORIGINALE and cardio*) or ((SELECT or FLOW) and semaglutide*) or (SCORED and Sotagliflozin) or (SURMOUNT and tirzepatide*) or SURMOUNT-1).mp. 628
49 or/41-48 [CVOTs] 4810
50 22 and 40 and 49 2229
51 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Equivalence Trial or Clinical Trial, Phase III).pt. 729347
52 Randomized Controlled Trial/ 633099
53 exp Randomized Controlled Trials as Topic/ 183329
54 Randomized Controlled Trial (topic)/ 0
55 Controlled Clinical Trial/ 95671
56 exp Controlled Clinical Trials as Topic/ 189185
57 Controlled Clinical Trial (topic)/ 0
58 Randomization/ 108155
59 Random Allocation/ 108155
60 Double-Blind Method/ 182972
61 Double Blind Procedure/ 0
62 Double-Blind Studies/ 182972
63 Single-Blind Method/ 34691
64 Single Blind Procedure/ 0
65 Single-Blind Studies/ 34691
66 Placebos/ 36069
67 Placebo/ 0
68 Control Groups/ 2145
69 Control Group/ 2145
70 (random* or sham or placebo*).ti,ab,hw,kf. 2002196
71 ((singl* or doubl*) adj (blind* or dumm* or mask*)).ti,ab,hw,kf. 283332
72 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).ti,ab,hw,kf. 2050
73 (control* adj3 (study or studies or trial* or group*)).ti,ab,kf. 1368425
74 (Nonrandom* or non random* or non-random* or quasi-random* or quasirandom*).ti,ab,hw,kf. 61036
75 allocated.ti,ab,hw. 93910
76 ((open label or open-label) adj5 (study or studies or trial*)).ti,ab,hw,kf. 50746
77 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).ti,ab,hw,kf. 14656
78 (pragmatic study or pragmatic studies).ti,ab,hw,kf. 698
79 ((pragmatic or practical) adj3 trial*).ti,ab,hw,kf. 9201
80 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).ti,ab,hw,kf. 15289
81 (phase adj3 (III or "3") adj3 (study or studies or trial*)).ti,hw,kf. 38992
82 or/51-81 [CADTH RCT Filter for Medline and Embase ] 2863052
83 50 and 82 1263
84 limit 83 to yr="2015 -Current" 1254